The Manufacturers Life Insurance Company Raises Stake in Illumina, Inc. (ILMN)

The Manufacturers Life Insurance Company grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 0.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 156,610 shares of the life sciences company’s stock after purchasing an additional 1,292 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in Illumina were worth $34,218,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Advisory Services Network LLC raised its stake in shares of Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in Illumina by 2.1% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 5,698 shares of the life sciences company’s stock worth $989,000 after buying an additional 116 shares during the period. Hemenway Trust Co LLC increased its stake in Illumina by 0.6% during the 4th quarter. Hemenway Trust Co LLC now owns 37,895 shares of the life sciences company’s stock worth $8,280,000 after buying an additional 227 shares during the period. Daiwa Securities Group Inc. increased its stake in Illumina by 4.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 5,543 shares of the life sciences company’s stock worth $1,211,000 after buying an additional 229 shares during the period. Finally, Private Asset Management Inc. increased its stake in Illumina by 2.2% during the 4th quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock worth $2,419,000 after buying an additional 240 shares during the period. 91.12% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $212.55, for a total value of $4,251,000.00. Following the completion of the transaction, the director now directly owns 505,980 shares of the company’s stock, valued at approximately $107,546,049. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $226.55, for a total transaction of $283,187.50. Following the completion of the transaction, the director now directly owns 9,088 shares of the company’s stock, valued at $2,058,886.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 95,848 shares of company stock valued at $21,414,125. 0.89% of the stock is owned by company insiders.

Illumina, Inc. (NASDAQ ILMN) opened at $226.57 on Wednesday. The firm has a market cap of $33,692.40, a price-to-earnings ratio of 57.16, a price-to-earnings-growth ratio of 3.03 and a beta of 0.92. The company has a current ratio of 3.99, a quick ratio of 3.55 and a debt-to-equity ratio of 0.43. Illumina, Inc. has a fifty-two week low of $158.02 and a fifty-two week high of $248.97.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.22. The company had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.71%. The firm’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same period last year, the business earned $0.85 EPS. sell-side analysts predict that Illumina, Inc. will post 4.59 earnings per share for the current year.

Several research firms recently issued reports on ILMN. Citigroup raised shares of Illumina from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $260.00 to $275.00 in a research note on Monday, February 5th. BidaskClub downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, February 3rd. Barclays lifted their price target on shares of Illumina from $200.00 to $215.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 31st. Morgan Stanley lifted their price target on shares of Illumina from $145.00 to $157.00 and gave the stock an “underweight” rating in a research note on Wednesday, January 31st. Finally, Leerink Swann lifted their price target on shares of Illumina from $250.00 to $276.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $241.39.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/21/the-manufacturers-life-insurance-company-raises-stake-in-illumina-inc-ilmn.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply